SEC Form 4 · accession 0001572426-15-000046
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph S McCracken
Director
Period of report
May 18, 2015
Accepted (ET)
May 20, 2015 · 6:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 18, 2015 | M | 1,400 | $0.125 | A | 3,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | May 18, 2015 | M | 900 | D | Mar 31, 2015 | Jul 1, 2019 | Ordinary Shares | 900 | 900 | D |
| Restricted Share UnitsF2 | $0.125 | May 18, 2015 | M | 500 | D | Mar 31, 2015 | Jul 1, 2019 | Ordinary Shares | 500 | 4,500 | D |
Explanation of responses
- F150% of the Restricted Share Units vested and became convertible on 3/31/15, and the remaining 50% shall vest and become convertible on 6/30/15, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
- F2500 of the Restricted Share Units vested and became convertible on 3/31/15, and shall vest and become convertible with respect to an additional 500 shares on each of 6/30/15, 9/30/15,12/31/15, 3/31/16, 6/30/16, 9/30/16, 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.